Walleye Capital LLC lowered its position in CorVel Corp. (NASDAQ:CRVL – Free Report) by 93.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,009 shares of the business services provider’s stock after selling 52,943 shares during the period. Walleye Capital LLC’s holdings in CorVel were worth $219,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. acquired a new position in shares of CorVel during the third quarter valued at about $31,000. Los Angeles Capital Management LLC bought a new position in CorVel in the 4th quarter valued at about $33,000. Eagle Bay Advisors LLC acquired a new position in CorVel during the 4th quarter valued at about $37,000. Rockefeller Capital Management L.P. boosted its stake in CorVel by 66.9% during the 4th quarter. Rockefeller Capital Management L.P. now owns 574 shares of the business services provider’s stock valued at $39,000 after purchasing an additional 230 shares during the last quarter. Finally, Quarry LP increased its holdings in CorVel by 218.6% during the 3rd quarter. Quarry LP now owns 513 shares of the business services provider’s stock worth $40,000 after purchasing an additional 352 shares in the last quarter. Institutional investors and hedge funds own 51.36% of the company’s stock.
CorVel Stock Performance
NASDAQ CRVL opened at $59.86 on Friday. The company has a market capitalization of $3.05 billion, a PE ratio of 27.97 and a beta of 0.98. CorVel Corp. has a 52-week low of $44.83 and a 52-week high of $93.71. The company has a 50-day simple moving average of $61.08 and a 200 day simple moving average of $58.45.
Wall Street Analyst Weigh In
CRVL has been the subject of several analyst reports. Weiss Ratings raised CorVel from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 16th. Wall Street Zen upgraded CorVel from a “hold” rating to a “buy” rating in a report on Saturday, May 30th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.
Read Our Latest Analysis on CorVel
Insider Transactions at CorVel
In related news, VP Jennifer Yoss sold 1,999 shares of CorVel stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $61.02, for a total value of $121,978.98. Following the sale, the vice president owned 2,173 shares of the company’s stock, valued at approximately $132,596.46. The trade was a 47.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey J. Michael sold 9,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $60.98, for a total value of $548,820.00. Following the completion of the transaction, the director owned 559,721 shares in the company, valued at approximately $34,131,786.58. The trade was a 1.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 13,249 shares of company stock worth $807,126 in the last quarter. Insiders own 39.72% of the company’s stock.
CorVel Profile
CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.
The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).
Featured Articles
- Five stocks we like better than CorVel
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Want to see what other hedge funds are holding CRVL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CorVel Corp. (NASDAQ:CRVL – Free Report).
Receive News & Ratings for CorVel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorVel and related companies with MarketBeat.com's FREE daily email newsletter.
